GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: INCY
Overweight $125
up 64.00 %

Incyte Corporation (NASDAQ: INCY) reiterated to Overweight with price target $125 by Barclays

Thursday,  Aug 13, 2015  12:25 PM ET by Betsy O'Brien Harrison

Barclays reiterated Incyte Corporation (NASDAQ: INCY) to Overweight with price target $125. Previously Barclays reiterated Incyte Corporation (NASDAQ: INCY) to Overweight with price target
$75 on 02/13/2014, when the stock price was $66.00. Since then, Incyte Corporation's stock price has gained 64% as of 08/13/2015's recent price of $108.44.
If you would have followed the previous Barclays's recommendation on INCY, you would have gained 64% of your investment in 546 days.

Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs. The Company has a pipeline with programs in oncology, inflammation and diabetes. Incyte?s pipeline includes compounds in various stages of development in the areas of oncology, inflammation, diabetes and human immunodeficiency virus (HIV).

Barclays



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy